| Description | Mean | Reference |
|---|---|---|
| Inputs from ESCAPE trial, efficacy of treatment at 90 d post AIS | ||
| IVT alone strategy, % | ||
| All-cause mortality | 19.0 | 14 |
| Functional independence | 29.3 | 14 |
| Cost in first 3 mo, weighted by health status; $CAD | 46 093 | 14,29 |
| MT + IVT strategy, % | ||
| All-cause mortality | 10.4 | 14 |
| Functional independence | 53.0 | 14 |
| Cost in first 3 mo, weighted by health status; $CAD | 51 961 | 14,29 |
| Inputs from Broderick and colleagues, severe stroke (National Institutes of Health Stroke Scale score ≥ 20) | 31 | |
| IVT alone strategy, % | ||
| All-cause mortality | 34 | 31 |
| Functional independence | 14 | 31 |
| Cost in first 3 mo, weighted by health status; $CAD | 51 988 | 29,31 |
| MT + IVT strategy | ||
| All-cause mortality, % | 34 | Assumption* |
| Odds ratio of functional independence, MT + IVT v. IVT alone | 1.97 | 31 |
| Cost in first 3 mo, weighted by health status; $CAD | 63 026 | 29,31 |
| Odds ratio of functional independence in subgroup patients, MT + IVT v. IVT; yr | ||
| ≤ 70 | 3.02 | 10-14 |
| > 70 | 1.79 | 10-14 |
| Including cost for cost of end-of-life care | ||
| Cost of end-of-life care for death after 90 d poststroke; $CAD | 50 892 | 32 |
Note: AIS = acute ischemic stroke, $CAD = Canadian dollars in 2015, IVT = intravenous thrombolysis, mRS = modified Rankin Scale, MT = mechanical thrombectomy.
*This study31 did not find a significant difference in mortality between groups (28.8% mRS 6 in the endovascular treatment group v. 34% in the IT group). Therefore, we assumed no survival benefit for MT in this scenario analysis.